Elsiglutide

Drug Profile

Elsiglutide

Alternative Names: ZP 1846

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zealand Pharma
  • Developer Helsinn; Zealand Pharma
  • Class Glucagon-like peptides
  • Mechanism of Action Glucagon-like peptide 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diarrhoea

Most Recent Events

  • 12 Jun 2017 Helsinn Healthcare returns its worldwide licensing rights to elsiglutide to Zealand Pharma
  • 02 Jun 2017 Preliminary adverse events data from a phase IIb trial in Diarrhoea presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 01 Feb 2016 Helsinn Healthcare completes a phase IIb trial in Diarrhoea (Chemotherapy-induced, Prevention) in Hungary, Germany, the Czech Republic, Russia, Bulgaria, Belarus, Poland and Ukraine (SC) (NCT02383810)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top